BIO-Europe® 2015 international life science partnering conference, held in Munich, Germany, November 2–4, 2015, expects over 3,300 delegates representing investors, biotech innovators and pharmaceutical executives from the global drug development industry.
Why Munich? Munich is home to a broad spectrum of high-capacity industries including life sciences; information and communication technology; automotive; aerospace; financial services; cross-industry technologies; skilled crafts; media/creative industries and corporate services. The City of Munich is a leading business location in Europe, the gross domestic product is (2011) is EUR 79.8 billion; the workforce (2011) is 981,100; Munich's economic structure is diverse: The famous "Munich Mix" comprises global players and SMEs, high-tech production and craftsmen, innovation and knowledge hubs, a huge startup community and diverse services.
Munich is the right place to meet innovation and innovators from all over the world. "BIO-Europe is a valuable forum for us to meet a wide range of companies," said Jeremy Springhorn, PhD, Partner, Corporate Development at Flagship Ventures. "We understand the importance of strategic partnerships, and BIO-Europe continues to be a productive event for building relationships."
"At Bristol-Myers Squibb, we have long since recognized that innovation happens everywhere and partnering has been an important part of our strategy for decades," said Mohamed Ragab, VP Oncology Search and Evaluation, Bristol-Myers Squibb. "We are always in search of partners who can help us continue to advance the science of immuno-oncology, and BIO-Europe enables us to evaluate a large number of companies and potential licensing opportunities in a short amount of time."
The Bavarian local host organisation, BioM, is managing a joint booth (#74), guides through the City and is pleased to welcome you in Munich.
further reading:
http://www.ebdgroup.com/bioeurope/index.php
http://www.bio-m.org/biom-veranstaltungen/bio-europe-2015-munich.html